Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Antibody-drug conjugates clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Antibody-drug conjugates as a study intervention. Browse Antibody-drug conjugates recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
503
Shown on this page
12
Current sort
Recently updated
Therapy scope
Antibody-drug conjugates
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Antibody-drug conjugates. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 337–348 of 503 matching trials for Antibody-drug conjugates.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

NCT04084366
View directory record Official record
Conditions
Locally Advanced Solid Tumor
Interventions
OBI-999
Drug
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
La Jolla, California • New York, New York • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Nov 7, 2026, 9:42 PM EST
Completed Phase 1Phase 2 Interventional Results available

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT03544281
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Goodyear, Arizona • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Nov 7, 2026, 9:42 PM EST
Completed Phase 1 Interventional Results available

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

NCT03523572
View directory record Official record
Conditions
Breast Cancer, Urothelial Carcinoma
Interventions
Trastuzumab deruxtecan, Nivolumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Nov 7, 2026, 9:42 PM EST
Completed Phase 1Phase 2 Interventional

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

NCT03504488
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Interventions
CAB-ROR2-ADC, PD-1 inhibitor
Biological
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Nov 7, 2026, 9:42 PM EST
Completed Phase 1Phase 2 Interventional Results available

First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors

NCT04622774
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
IMGC936
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
La Jolla, California • Denver, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Nov 7, 2026, 9:42 PM EST
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

NCT02980341
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Patritumab Deruxtecan
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Newnan, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Nov 7, 2026, 9:42 PM EST
Not listed Phase 1Phase 2 Interventional

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

NCT04492488
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
Interventions
MRG002
Drug
Lead sponsor
Shanghai Miracogen Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Orange, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Nov 7, 2026, 9:42 PM EST
Completed Phase 1 Interventional

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

NCT04147819
View directory record Official record
Conditions
Cancers With HER2 Expression
Interventions
BAY2701439
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Nov 7, 2026, 9:42 PM EST
Recruiting Phase 1Phase 2 Interventional

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

NCT06525298
View directory record Official record
Conditions
Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
Interventions
EIS-12656, Olaparib, Trastuzumab deruxtecan
Drug
Lead sponsor
Eisbach Bio GmbH
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 7, 2026, 9:42 PM EST
Terminated Phase 2 Interventional Results available

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT04659044
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human, Venetoclax
Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Sioux City, Iowa • Ann Arbor, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 7, 2026, 9:42 PM EST
Terminated Phase 1 Interventional

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

NCT04036461
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-99712, BMS-986405
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
La Jolla, California • Sarasota, Florida • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Nov 7, 2026, 9:42 PM EST
Completed Phase 2 Interventional Results available

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT03219333
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
Interventions
Enfortumab vedotin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
54
States / cities
Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Nov 7, 2026, 9:42 PM EST

About this Antibody-drug conjugates clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Antibody-drug conjugates as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Antibody-drug conjugates.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Antibody-drug conjugates.